Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1966 1
1967 3
1968 2
1970 4
1971 1
1972 3
1973 1
1974 4
1975 1
1976 5
1978 3
1979 4
1980 3
1981 3
1982 4
1983 6
1984 2
1985 7
1986 3
1987 2
1988 3
1989 4
1990 3
1991 2
1992 4
1993 1
1994 4
1995 4
1997 2
1998 9
1999 7
2000 10
2001 6
2002 4
2003 10
2004 10
2005 10
2006 8
2007 14
2008 13
2009 19
2010 20
2011 24
2012 33
2013 22
2014 31
2015 21
2016 33
2017 24
2018 18
2019 20
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

430 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Free article. Clinical Trial.
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. ...Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported ou …
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II …
Dermoscopy in General Dermatology: A Practical Overview.
Errichetti E, Stinco G. Errichetti E, et al. Dermatol Ther (Heidelb). 2016 Dec;6(4):471-507. doi: 10.1007/s13555-016-0141-6. Epub 2016 Sep 9. Dermatol Ther (Heidelb). 2016. PMID: 27613297 Free PMC article. Review.
In this article, we sought to provide an up-to-date practical overview on the use of dermoscopy in general dermatology by analysing the dermoscopic differential diagnosis of relatively common dermatological disorders grouped according to their clinical presentation, i.e. dermatos …
In this article, we sought to provide an up-to-date practical overview on the use of dermoscopy in general dermatology by analysing the derm …
[Psoriasis capitis and seborrhoic eczema of scalp diseases].
Sticherling M. Sticherling M. Hautarzt. 2017 Jun;68(6):457-465. doi: 10.1007/s00105-017-3986-4. Hautarzt. 2017. PMID: 28567508 Review. German.
The scalp may be affected by various diseases with equally varying manifestations. Erythema and scaling is often accompanied by agonizing itch. Scalp psoriasis and seborrheic eczema represent the most frequent diseases, which can be differentiated into classi …
The scalp may be affected by various diseases with equally varying manifestations. Erythema and scaling is often accompanied by agoni …
Topical Therapies in Psoriasis.
Torsekar R, Gautam MM. Torsekar R, et al. Indian Dermatol Online J. 2017 Jul-Aug;8(4):235-245. doi: 10.4103/2229-5178.209622. Indian Dermatol Online J. 2017. PMID: 28761838 Free PMC article. Review.
Vitamin D analogs alone in combination with TCS are useful in stable plaques over limbs and palmoplantar psoriasis. Topical therapies for scalp psoriasis include TCS, Vitamin D analogs, salicylic acid, coal tar, and anthralin in various formulations such as s …
Vitamin D analogs alone in combination with TCS are useful in stable plaques over limbs and palmoplantar psoriasis. Topical therapies …
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M. Bagel J, et al. J Am Acad Dermatol. 2017 Oct;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033. Epub 2017 Aug 2. J Am Acad Dermatol. 2017. PMID: 28780364 Free article. Clinical Trial.
BACKGROUND: Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis. ...CONCLUSION: Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe s
BACKGROUND: Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-se …
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. Rich P, et al. J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001. J Am Acad Dermatol. 2016. PMID: 26549249 Free article. Clinical Trial.
A priori efficacy analyses included patients with nail (target nail Nail Psoriasis Severity Index score ≥1) and moderate to very severe scalp (Scalp Physician Global Assessment score ≥3) psoriasis at baseline. ...LIMITATIONS: Baseline randomization was …
A priori efficacy analyses included patients with nail (target nail Nail Psoriasis Severity Index score ≥1) and moderate to very seve …
Dermoscopic findings in scalp psoriasis and seborrheic dermatitis; two new signs; signet ring vessel and hidden hair.
Kibar M, Aktan Ş, Bilgin M. Kibar M, et al. Indian J Dermatol. 2015 Jan-Feb;60(1):41-5. doi: 10.4103/0019-5154.147786. Indian J Dermatol. 2015. PMID: 25657395 Free PMC article.
BACKGROUND: Psoriasis and seborrheic dermatitis are both chronic erythemato-squamous dermatoses that can involve the scalp. It may be difficult to differentiate these two diseases when there is isolated scalp involvement. ...OBJECTIVES: The objective of this …
BACKGROUND: Psoriasis and seborrheic dermatitis are both chronic erythemato-squamous dermatoses that can involve the scalp. It …
Dermoscopic features of psoriasis of the skin, scalp and nails - a systematic review.
Golińska J, Sar-Pomian M, Rudnicka L. Golińska J, et al. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):648-660. doi: 10.1111/jdv.15344. J Eur Acad Dermatol Venereol. 2019. PMID: 30422349
To date, no systematic review about the diagnostic usability of dermoscopy in psoriasis has been available. The objective of this article was to summarize and critically analyse literature data on the dermoscopy of skin, scalp and nail changes in psoriasis. . …
To date, no systematic review about the diagnostic usability of dermoscopy in psoriasis has been available. The objective of this art …
Psoriasis in special localizations.
Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Dopytalska K, et al. Reumatologia. 2018;56(6):392-398. doi: 10.5114/reum.2018.80718. Epub 2018 Dec 23. Reumatologia. 2018. PMID: 30647487 Free PMC article. Review.
Psoriasis is a chronic inflammatory dermatosis affecting 1-3% of the general population. Patients with psoriasis represent a heterogeneous population with individual disease expression - different degrees and severity of skin involvement. Psoriatic lesions in partic
Psoriasis is a chronic inflammatory dermatosis affecting 1-3% of the general population. Patients with psoriasis represent a h
Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.
Merola JF, Qureshi A, Husni ME. Merola JF, et al. Dermatol Ther. 2018 May;31(3):e12589. doi: 10.1111/dth.12589. Epub 2018 Mar 6. Dermatol Ther. 2018. PMID: 29512290 Free PMC article. Review.
Psoriasis of the scalp, face, intertriginous areas, genitals, hands, feet, and nails is often underdiagnosed, and disease management can be challenging. ...We also examine clinical studies evaluating the effectiveness of therapies on psoriasis in these region
Psoriasis of the scalp, face, intertriginous areas, genitals, hands, feet, and nails is often underdiagnosed, and disease mana
430 results
Jump to page
Feedback